Mylan's Epic EpiPen Price Hike Wasn't About Greed -- It's Worse, Lawsuit Claims (arstechnica.com)

Mylan engaged in a campaign to squash a rival to its EpiPen allergy treatment and artificially inflate the price of the drug to maintain a market monopoly, French drugmaker Sanofi said in a lawsuit. From a report: With the lofty prices and near-monopoly over the market, Mylan could dangle deep discounts to drug suppliers -- with the condition that they turn their backs on Sanofi's Auvi-Q -- the lawsuit alleges. Suppliers wouldn't dare ditch EpiPens, the most popular auto-injector. And with the high prices, the rebates wouldn't put a dent in Mylan's hefty profits, Sanofi speculates. Coupled with a smear campaign and other underhanded practices, Mylan effectively pushed Sanofi out of the US epinephrine auto-injector market, Sanofi alleges. The lawsuit, filed Monday in a federal court in New Jersey, seeks damages under US Antitrust laws.

Comments

Damages

[Anonymous Coward]

If Sanofi proves its case, the judge should permanently revoke all patents in and related to EpiPen.

Let's see which drug manufacturer wants to be the next one to kill the golden goose after that ruling.

Mylan: Corporate Death Penalty

[WCMI92]

Their behavior deserves it. Their corporation is dissolved, all their executives (including Mizz Bresch) are banned from working in similar positions for life, and all their intellectual property is public domain.

EpiPen in Canada

[Anonymous Coward]

is $14.00 for two.

Just FYI.